Literature DB >> 30887214

Inflammation and fibrosis in murine models of heart failure.

Lucas Bacmeister1,2, Michael Schwarzl3,4, Svenja Warnke3,4, Bastian Stoffers3,4, Stefan Blankenberg3,4, Dirk Westermann3,4, Diana Lindner5,6.   

Abstract

Heart failure is a consequence of various cardiovascular diseases and associated with poor prognosis. Despite progress in the treatment of heart failure in the past decades, prevalence and hospitalisation rates are still increasing. Heart failure is typically associated with cardiac remodelling. Here, inflammation and fibrosis are thought to play crucial roles. During cardiac inflammation, immune cells invade the cardiac tissue and modulate tissue-damaging responses. Cardiac fibrosis, however, is characterised by an increased amount and a disrupted composition of extracellular matrix proteins. As evidence exists that cardiac inflammation and fibrosis are potentially reversible in experimental and clinical set ups, they are interesting targets for innovative heart failure treatments. In this context, animal models are important as they mimic clinical conditions of heart failure patients. The advantages of mice in this respect are short generation times and genetic modifications. As numerous murine models of heart failure exist, the selection of a proper disease model for a distinct research question is demanding. To facilitate this selection, this review aims to provide an overview about the current understanding of the pathogenesis of cardiac inflammation and fibrosis in six frequently used murine models of heart failure. Hence, it compares the models of myocardial infarction with or without reperfusion, transverse aortic constriction, chronic subjection to angiotensin II or deoxycorticosterone acetate, and coxsackievirus B3-induced viral myocarditis in this context. It furthermore provides information about the clinical relevance and the limitations of each model, and, if applicable, about the recent advancements in their methodological proceedings.

Entities:  

Keywords:  Cardiac hypertrophy; Ischemia/reperfusion; Myocardial infarction (MI); Myocarditis; Neurohumoral activation; Pressure overload

Mesh:

Year:  2019        PMID: 30887214     DOI: 10.1007/s00395-019-0722-5

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  96 in total

Review 1.  BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.

Authors:  Patricia Cristine Borck; Lian-Wang Guo; Jorge Plutzky
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

2.  Fibroblast growth factor-inducible 14 mediates macrophage infiltration in heart to promote pressure overload-induced cardiac dysfunction.

Authors:  Sathya D Unudurthi; Drew M Nassal; Nehal J Patel; Evelyn Thomas; Jane Yu; Curtis G Pierson; Shyam S Bansal; Peter J Mohler; Thomas J Hund
Journal:  Life Sci       Date:  2020-02-15       Impact factor: 5.037

Review 3.  Emerging therapies for right ventricular dysfunction and failure.

Authors:  Anna Klinke; Torben Schubert; Marion Müller; Ekaterina Legchenko; Jason G E Zelt; Tsukasa Shimauchi; L Christian Napp; Alexander M K Rothman; Sébastien Bonnet; Duncan J Stewart; Georg Hansmann; Volker Rudolph
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

4.  Quantitative analysis of variability in an integrated model of human ventricular electrophysiology and β-adrenergic signaling.

Authors:  Jingqi Q X Gong; Monica E Susilo; Anna Sher; Cynthia J Musante; Eric A Sobie
Journal:  J Mol Cell Cardiol       Date:  2020-04-21       Impact factor: 5.000

5.  A Retinoic Acid Receptor β 2 Agonist Improves Cardiac Function in a Heart Failure Model.

Authors:  Xiao-Han Tang; Jessica Gambardella; Stanislovas Jankauskas; Xujun Wang; Gaetano Santulli; Lorraine J Gudas; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2021-08-13       Impact factor: 4.030

Review 6.  Pathogenesis of arrhythmogenic cardiomyopathy: role of inflammation.

Authors:  Yen-Nien Lin; Ahmed Ibrahim; Eduardo Marbán; Eugenio Cingolani
Journal:  Basic Res Cardiol       Date:  2021-06-04       Impact factor: 17.165

7.  SPARC production by bone marrow-derived cells contributes to myocardial fibrosis in pressure overload.

Authors:  Hannah J Riley; Ryan R Kelly; An O Van Laer; Lily S Neff; Shaoni Dasgupta; Catalin F Baicu; Lindsay T McDonald; Amanda C LaRue; Michael R Zile; Amy D Bradshaw
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-12-11       Impact factor: 4.733

8.  Immune cell Dilemma in Ischemic Cardiomyopathy: To Heal or Not to Heal.

Authors:  Sarita Nehra; Richard J Gumina; Shyam S Bansal
Journal:  Curr Opin Physiol       Date:  2020-09-10

Review 9.  Critical roles of macrophages in pressure overload-induced cardiac remodeling.

Authors:  Dan Yang; Han-Qing Liu; Fang-Yuan Liu; Nan Tang; Zhen Guo; Shu-Qing Ma; Peng An; Ming-Yu Wang; Hai-Ming Wu; Zheng Yang; Di Fan; Qi-Zhu Tang
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

10.  Inhibition of Long Noncoding RNA SNHG20 Improves Angiotensin II-Induced Cardiac Fibrosis and Hypertrophy by Regulating the MicroRNA 335/Galectin-3 Axis.

Authors:  Mingyang Li; Chunli Qi; Renxing Song; Chunming Xiong; Xiao Zhong; Ziguang Song; Zhongping Ning; Xiang Song
Journal:  Mol Cell Biol       Date:  2021-08-24       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.